FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802085197> ?p ?o ?g. }

• W2802085197 endingPage "1926" @default.
• W2802085197 startingPage "1916" @default.
• W2802085197 abstract "BackgroundPotentially untreatable Plasmodium falciparum malaria threatens the Greater Mekong subregion. A previous series of pilot projects in Myanmar, Laos, Cambodia, and Vietnam suggested that mass drug administration was safe, and when added to provision of early diagnosis and treatment, could reduce the reservoir of P falciparum and interrupts transmission. We examined the effects of a scaled-up programme of this strategy in four townships of eastern Myanmar on the incidence of P falciparum malaria.MethodsThe programme was implemented in the four townships of Myawaddy, Kawkareik, Hlaingbwe, and Hpapun in Kayin state, Myanmar. Increased access to early diagnosis and treatment of malaria was provided to all villages through community-based malaria posts equipped with rapid diagnostic tests, and treatment with artemether–lumefantrine plus single low-dose primaquine. Villages were identified as malarial hotspots (operationally defined as >40% malaria, of which 20% was P falciparum) with surveys using ultrasensitive quantitative PCR either randomly or targeted at villages where the incidence of clinical cases of P falciparum malaria remained high (ie, >100 cases per 1000 individuals per year) despite a functioning malaria post. During each survey, a 2 mL sample of venous blood was obtained from randomly selected adults. Hotspots received targeted mass drug administration with dihydroartemisinin–piperaquine plus single-dose primaquine once per month for 3 consecutive months in addition to the malaria posts. The main outcome was the change in village incidence of clinical P falciparum malaria, quantified using a multivariate, generalised, additive multilevel model. Malaria prevalence was measured in the hotspots 12 months after mass drug administration.FindingsBetween May 1, 2014, and April 30, 2017, 1222 malarial posts were opened, providing early diagnosis and treatment to an estimated 365 000 individuals. Incidence of P falciparum malaria decreased by 60 to 98% in the four townships. 272 prevalence surveys were undertaken and 69 hotspot villages were identified. By April 2017, 50 hotspots were treated with mass drug administration. Hotspot villages had a three times higher incidence of P falciparum at malarial posts than neighbouring villages (adjusted incidence rate ratio [IRR] 2·7, 95% CI 1·8–4·4). Early diagnosis and treatment was associated with a significant decrease in P falciparum incidence in hotspots (IRR 0·82, 95% CI 0·76–0·88 per quarter) and in other villages (0·75, 0·73–0·78 per quarter). Mass drug administration was associated with a five-times decrease in P falciparum incidence within hotspot villages (IRR 0·19, 95% CI 0·13–0·26). By April, 2017, 965 villages (79%) of 1222 corresponding to 104 village tracts were free from P falciparum malaria for at least 6 months. The prevalence of wild-type genotype for K13 molecular markers of artemisinin resistance was stable over the three years (39%; 249/631).InterpretationProviding early diagnosis and effective treatment substantially decreased village-level incidence of artemisinin-resistant P falciparum malaria in hard-to-reach, politically sensitive regions of eastern Myanmar. Targeted mass drug administration significantly reduced malaria incidence in hotspots. If these activities could proceed in all contiguous endemic areas in addition to standard control programmes already implemented, there is a possibility of subnational elimination of P falciparum.FundingThe Bill & Melinda Gates Foundation, the Regional Artemisinin Initiative (Global Fund against AIDS, Tuberculosis and Malaria), and the Wellcome Trust." @default.
• W2802085197 created "2018-05-17" @default.
• W2802085197 creator A5001342115 @default.
• W2802085197 creator A5002056442 @default.
• W2802085197 creator A5002678704 @default.
• W2802085197 creator A5003242293 @default.
• W2802085197 creator A5003262926 @default.
• W2802085197 creator A5003594729 @default.
• W2802085197 creator A5005021967 @default.
• W2802085197 creator A5005518862 @default.
• W2802085197 creator A5010424128 @default.
• W2802085197 creator A5010512581 @default.
• W2802085197 creator A5014977844 @default.
• W2802085197 creator A5016306670 @default.
• W2802085197 creator A5016728141 @default.
• W2802085197 creator A5018095795 @default.
• W2802085197 creator A5019519150 @default.
• W2802085197 creator A5020017456 @default.
• W2802085197 creator A5020307232 @default.
• W2802085197 creator A5021147780 @default.
• W2802085197 creator A5021610593 @default.
• W2802085197 creator A5023461123 @default.
• W2802085197 creator A5023854939 @default.
• W2802085197 creator A5024616654 @default.
• W2802085197 creator A5027378026 @default.
• W2802085197 creator A5027511873 @default.
• W2802085197 creator A5029173731 @default.
• W2802085197 creator A5029292055 @default.
• W2802085197 creator A5031849214 @default.
• W2802085197 creator A5032089855 @default.
• W2802085197 creator A5032394349 @default.
• W2802085197 creator A5033814922 @default.
• W2802085197 creator A5034097318 @default.
• W2802085197 creator A5034583694 @default.
• W2802085197 creator A5036739273 @default.
• W2802085197 creator A5037722387 @default.
• W2802085197 creator A5037824287 @default.
• W2802085197 creator A5038537091 @default.
• W2802085197 creator A5040074473 @default.
• W2802085197 creator A5040134709 @default.
• W2802085197 creator A5040674854 @default.
• W2802085197 creator A5041461188 @default.
• W2802085197 creator A5043263263 @default.
• W2802085197 creator A5044209014 @default.
• W2802085197 creator A5045825632 @default.
• W2802085197 creator A5046052766 @default.
• W2802085197 creator A5046547648 @default.
• W2802085197 creator A5046660044 @default.
• W2802085197 creator A5048666821 @default.
• W2802085197 creator A5048858297 @default.
• W2802085197 creator A5049897185 @default.
• W2802085197 creator A5051408897 @default.
• W2802085197 creator A5052502655 @default.
• W2802085197 creator A5053525573 @default.
• W2802085197 creator A5054366044 @default.
• W2802085197 creator A5054615698 @default.
• W2802085197 creator A5055118698 @default.
• W2802085197 creator A5056545839 @default.
• W2802085197 creator A5057491951 @default.
• W2802085197 creator A5057645802 @default.
• W2802085197 creator A5058405851 @default.
• W2802085197 creator A5058904890 @default.
• W2802085197 creator A5060277325 @default.
• W2802085197 creator A5064467734 @default.
• W2802085197 creator A5064485154 @default.
• W2802085197 creator A5065038051 @default.
• W2802085197 creator A5065314470 @default.
• W2802085197 creator A5069329911 @default.
• W2802085197 creator A5070176699 @default.
• W2802085197 creator A5070200817 @default.
• W2802085197 creator A5073904570 @default.
• W2802085197 creator A5074946841 @default.
• W2802085197 creator A5075689582 @default.
• W2802085197 creator A5075830207 @default.
• W2802085197 creator A5076261440 @default.
• W2802085197 creator A5077392642 @default.
• W2802085197 creator A5077748740 @default.
• W2802085197 creator A5078630446 @default.
• W2802085197 creator A5080378607 @default.
• W2802085197 creator A5086922076 @default.
• W2802085197 creator A5087463614 @default.
• W2802085197 creator A5090287224 @default.
• W2802085197 creator A5090518483 @default.
• W2802085197 date "2018-05-01" @default.
• W2802085197 modified "2023-10-16" @default.
• W2802085197 title "Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme" @default.
• W2802085197 cites W1485474720 @default.
• W2802085197 cites W1824454329 @default.
• W2802085197 cites W1979437702 @default.
• W2802085197 cites W1984669077 @default.
• W2802085197 cites W1987311633 @default.
• W2802085197 cites W2032150053 @default.
• W2802085197 cites W2062863104 @default.
• W2802085197 cites W2102395543 @default.
• W2802085197 cites W2119129399 @default.
• W2802085197 cites W2141699230 @default.
• W2802085197 cites W2145094277 @default.
• W2802085197 cites W2165691527 @default.

• next